Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Bone marrow is the preferred site of memory CD4+ T cell proliferation during recovery from sepsis
Tomasz Skirecki, Patrycja Swacha, Grażyna Hoser, Jakub Golab, Dominika Nowis, Ewa Kozłowska
Tomasz Skirecki, Patrycja Swacha, Grażyna Hoser, Jakub Golab, Dominika Nowis, Ewa Kozłowska
View: Text | PDF
Research Article Immunology Infectious disease

Bone marrow is the preferred site of memory CD4+ T cell proliferation during recovery from sepsis

  • Text
  • PDF
Abstract

Sepsis survivors suffer from increased vulnerability to infections, and lymphopenia presumably contributes to this problem. The mechanisms of the recovery of memory CD4+ T cells after sepsis remain elusive. We used the cecal ligation and puncture mouse model of sepsis to study the restoration of the memory CD4+ T cells during recovery from sepsis. Then, adoptive transfer of antigen-specific naive CD4+ T cells followed by immunization and BrdU labeling were performed to trace the proliferation and migration of memory CD4+ T cells. We revealed that the bone marrow (BM) is the primary site of CD4+ memory T cell homing and proliferation after sepsis-induced lymphopenia. Of interest, BM CD4+ T cells had a higher basal proliferation rate in comparison with splenic T cells. These cells also show features of resident memory T cells yet have the capacity to migrate outside the BM niche and engraft secondary lymphoid organs. The BM niche also sustains viability and functionality of CD4+ T cells. We also identified IL-7 as the major inducer of proliferation of the BM memory CD4+ T cells and showed that recombinant IL-7 improves the recovery of these cells. Taken together, we provide data on the mechanism and location of memory CD4+ T cell proliferation during recovery from septic lymphopenia, which are of relevance in studying immunostimulatory therapies in sepsis.

Authors

Tomasz Skirecki, Patrycja Swacha, Grażyna Hoser, Jakub Golab, Dominika Nowis, Ewa Kozłowska

×

Figure 4

BM supports proliferation of specific Ag-experienced memory CD4+ T cells in sepsis.

Options: View larger image (or click on image) Download as PowerPoint
BM supports proliferation of specific Ag-experienced memory CD4+ T cells...
(A) Experimental design. CD4+CD44– naive T cells were isolated from young OT-II mice and transferred to C57BL/6 recipients. Then, mice were immunized with 100 μg of OVA i.p. and 100 μg s.c. Thirty days later mice were subjected to CLP and received a bolus of BrdU on day 6 after surgery. Cells were analyzed 24 hours or 30 days later by flow cytometry. (B) Plots showing flow cytometry gating strategy of the transplanted I-Ab OVA329–337 tetramer-specific CD4+ T cells after nanobead enrichment. (C) Representative flow cytometry plots showing analysis of BrdU+ cells that are CD4+I-Ab OVA329-337+CD44+ from mice that had CLP surgery 7 days (upper row) and 36 days (lower row) before. (D) Total number of the I-Ab OVA CD4+BrdU+ cells in lymph nodes, spleen, and BM of mice post-CLP and sham mice at different times after BrdU injection. (E) Percentage of BrdU+ cells among the I-Ab OVA CD4+ cells in lymph nodes, spleen, and BM of mice post-CLP and sham mice at different times after BrdU injection. (F) Normalized ratios of the number of I-Ab OVA CD4+BrdU+ cells in the lymph nodes and BM versus the number of I-Ab OVA+CD4+BrdU+ in the spleen. Box-and-whiskers plot presents p25-p75 (box), mean, and p10-p90 (whiskers). Results from the mice post-CLP and sham mice at different times after BrdU injection. Data from 2 independent experiments (n = 6–10 in each group). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 using ANOVA with Tukey’s post hoc test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts